The NATO Innovation Fund (NIF), NATO's venture capital arm, has made its inaugural investment in a biotechnology company. NIF is co-leading a $35 million Series A funding round for Portal Biotech, a UK-based startup developing AI-powered diagnostic devices for rapid pathogen detection. Portal's technology aims to strengthen NATO's defenses against biological warfare by providing portable, on-site identification of biological threats at the single-molecule level. This differs from traditional lab-based diagnostics, offering crucial field deployment capabilities for enhanced defense and security. The investment highlights NATO's commitment to supporting innovative technologies that bolster its security infrastructure.